drugset / Trial / NCT03879772
Dose-Ranging Study of Mometasone Furoate (MK-0887/SCH 032088) Nasal Spray in the Treatment of Children (Ages 6-11) With Seasonal Allergic Rhinitis (C95-161)
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study was to identify the lowest dosage of mometasone furoate nasal spray (MFNS) that provided adequate efficacy with an acceptable safety profile for children (ages 6-11) with seasonal allergic rhinitis (SAR). The MFNS dose levels of 25, 100, and 200 mcg QD were compared with beclomethasone dipropionate (BDP), as an active control, and placebo.
Timeline
- Start
- 1996-03-12
- Primary completion
- 1996-07-01
- Completion
- 1996-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mometasone furoate | Other / unclassified | 25 ug | Intranasal |
| Subject | Mometasone furoate | Other / unclassified | 100 ug | Intranasal |
| Subject | Mometasone furoate | Other / unclassified | 200 ug | Intranasal |
| Comparator | beclomethasone dipropionate | Other / unclassified | 84 ug | Intranasal |
| Background | Chlorpheniramine | Unknown | 0.4 mg/ml | Oral |